- Home
- LFT vs COYA Comparison
LFT vs COYA Comparison
Compare LFT & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- COYA
- Stock Information
- Founded
- LFT 2012
- COYA 2020
- Country
- LFT United States
- COYA United States
- Employees
- LFT N/A
- COYA N/A
- Industry
- LFT Real Estate Investment Trusts
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- COYA Health Care
- Exchange
- LFT Nasdaq
- COYA Nasdaq
- Market Cap
- LFT 109.9M
- COYA 107.0M
- IPO Year
- LFT N/A
- COYA 2022
- Fundamental
- Price
- LFT $2.23
- COYA $6.86
- Analyst Decision
- LFT Hold
- COYA Strong Buy
- Analyst Count
- LFT 2
- COYA 4
- Target Price
- LFT N/A
- COYA $16.50
- AVG Volume (30 Days)
- LFT 157.0K
- COYA 52.8K
- Earning Date
- LFT 08-08-2025
- COYA 08-12-2025
- Dividend Yield
- LFT 11.21%
- COYA N/A
- EPS Growth
- LFT N/A
- COYA N/A
- EPS
- LFT 0.18
- COYA N/A
- Revenue
- LFT $25,803,999.00
- COYA $423,452.00
- Revenue This Year
- LFT $139.76
- COYA $40.52
- Revenue Next Year
- LFT N/A
- COYA N/A
- P/E Ratio
- LFT $12.39
- COYA N/A
- Revenue Growth
- LFT N/A
- COYA N/A
- 52 Week Low
- LFT $2.05
- COYA $4.65
- 52 Week High
- LFT $2.84
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- LFT 52.16
- COYA 62.90
- Support Level
- LFT $2.09
- COYA $5.86
- Resistance Level
- LFT $2.33
- COYA $6.28
- Average True Range (ATR)
- LFT 0.08
- COYA 0.40
- MACD
- LFT 0.00
- COYA 0.05
- Stochastic Oscillator
- LFT 60.00
- COYA 97.67
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.